Didscussion  by unknown
9. Resch T, Malina M, Lindblad B, Malina J, Brunkwall J, Ivancev K.
The impact of stent design on proximal stent-graft fixation in the
abdominal aorta: an experimental study. Eur J Vasc Endovasc Surg
2000;20:190-5.
10. Matsumura JS, Hoff FL, Pearce WH. Incidence and causes of proximal
device migration after EVAR. Paper presented at: VEITH symposium;
November 21, 2002; New York.
11. Lee JT, Lee J, Aziz I, Donayre CE, Walot I, Kopchok GE, et al.
Stent-graft migration following endovascular repair of aneurysms with
large proximal necks: anatomical risk factors and long-term sequeli. J
Endovasc Ther 2002;9:652-64.
12. Schurink GWH, Aarts NJM, van Baalen JM, Kool LJS, van Bockel JH.
Stent attachment site-related endoleakage after stent graft treatment: an
in vitro study of the effects of graft size, stent type, and atherosclerotic
wall changes. J Vasc Surg 1999;30:658-67.
13. Sternbergh WC III, Conners MS III, Tonnenson B, Carter G, Money
SR. Aortic aneurysm sac shrinkage after endovascular repair is device
dependent: a comparison of Zenith and AneuRx endografts. Ann Vasc
Surg 2003;17:49-53.
14. Zarins CK, White RA, Hodgson KJ, Schwarten D, Fogarty TJ. En-
doleak as a predictor of outcome after endovascular aneurysm repair:
AneuRx multicenter clinical trial. J Vasc Surg 2000;32:90-107.
15. Zarins CK, for the AneuRx Clinical Investigators. The US AneuRx
clinical trial: 6-year clinical update 2002. J Vasc Surg 2003;37:904-8.
16. Matsumura JS, Brewster DC, Makaroun MS, Naftel DC. A multicenter
controlled clinical trial of open versus endovascular treatment of ab-
dominal aortic aneurysms. J Vasc Surg 2003;37:262-71.
Submitted Jun 11, 2003; accepted Sep 20, 2003.
DISCUSSION
Dr Wesley S. Moore (Los Angeles, Calif). This was an
excellent presentation and superbly analyzed; however, I’m still
not totally convinced that the adverse effect of migration is related
to the oversizing of the prosthesis. It is more likely related to the
reasons that oversizing was selected to begin with.
You mentioned two possible reasons, including short neck or
extreme angulation; perhaps there are more. These reasons for
oversizing reflect the adverse effect based on patient selection
rather than the generic consequence of oversizing per se. Clearly,
there is no reason that one would want to excessively oversize
unless you were trying to compensate for some particular adverse
anatomic problem. Clearly there was a trend toward shorter necks
in your series. Even though this trend wasn’t statistically significant
in your analysis, that may be a sample size problem and a type II
error. Would you like to comment?
Dr Charles Sternbergh III. Thank you for those comments,
and I couldn’t agree more. We looked very hard for anatomic
characteristics that might explain the correlation between 30%
device oversizing and adverse events. As shown in this presenta-
tion, we could not identify any statistically significant associations;
aortic neck length did trend shorter, although the differences were
not statistically significant. The rate of endoleak was half of that in
the patients who were oversized less than 30% than in the patients
who were oversized greater than 30%, but this too was not statis-
tically significant. Increased endoleak rates have correlated with a
decrease in the chance of aneurysm shrinkage; but again, those
trends were not significant.
Dr Jacob Buth (Eindhoven, The Netherlands). I also would
like to congratulate Dr Sternbergh for an excellent paper. My
question is this: How did you get to the threshold of 30%? Was this
handpicked or was there any graphical or mathematical method
used, like a ROC curve?
Dr Sternbergh. That’s an excellent question. No, there were
not ROC curves developed for this study. Thirty percent was
chosen because it was double the size of the recommended maxi-
mum oversizing, which was 10% to 15%.
Dr David C. Brewster (Boston, Mass). Dr. Sternbergh, I’m a
little surprised about migration with suprarenal hooks. I can un-
derstand where oversizing of a device without such fixation might
be associated with a higher incidence of migration, but wouldn’t
one expect that suprarenal hook fixation would prevent that? And
secondly, as a participant in the Zenith trial, the device selection
was pretty tightly controlled, as I remember, by the sponsor, so
why would 30% oversizing occur in certain patients if that wasn’t
desirable?
Dr Sternbergh. I’ll start with your first question. I agree that
any incidence of migration, frankly, was somewhat surprising based
on the suprarenal barb fixation. But the data do suggest a small
chance of migration (25 mm) despite the suprarenal fixation.
In regard to the choice of oversizing, I, too, was surprised to
find that a number of the patients had this excessive oversizing.
And while I too recall that there was some significant oversight in
terms of sizing of these devices, it was ultimately left to the
discretion of the investigator.
Dr Piergiorgio Cao (Perugia, Italy). You report low inci-
dence of migration, which is quite different from our experience.
We had a higher incidence of migration with a different kind of
endograft: the highest peak migration was after 2 years. You
reported the results after 1 year. Do you have any other data after
this interval?
And the second question is this: since you couldn’t find any
correlation between migration and neck dilatation, can you spec-
ulate where this migration is coming from? What is the cause since,
you have no
Dr Sternbergh. I very much agree with you that migration is
a time-dependent phenomenon and 12 months is fairly early. I
don’t have any available data yet on more long-term migration, but
certainly that’s going to be an important thing to keep an eye on.
Your last question really is another question of why are these
migrating. And the bottom line is that we don’t know. We looked
very hard for other anatomic characteristics that perhaps were the
causative factor(s), and the 30% oversizing was simply a surro-
gate, but we could not find them.
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